Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition

Martina Di Modica, Lucia Sfondrini, Viola Regondi, Stefania Varchetta, Barbara Oliviero, Gabriella Mariani, Giulia Valeria Bianchi, Daniele Generali, Andrea Balsari, Tiziana Triulzi, Elda Tagliabue

Research output: Contribution to journalArticle

Abstract

Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In HER2+ BC experimental models and patients, we investigated whether this synergy depends on the ability of drug-induced stress to improve NK cell effectiveness and thus trastuzumab-mediated ADCC. HER2+ BC cell lines BT474 and MDAMB361 treated with docetaxel showed up-modulation of NK activator ligands both in vitro and in vivo, accompanied by a 15-40% increase in in vitro trastuzumab-mediated ADCC; antibodies blocking the NKG2D receptor significantly reduced this enhancement. NKG2D receptor expression was increased by docetaxel treatment in circulating and splenic NK cells from mice xenografted with tumor cells, an increase related to expansion of the CD11b+Ly6G+ cell population. Accordingly, NK cells derived from HER2+ BC patients after treatment with taxane-containing therapy expressed higher levels of NKG2D receptor than before treatment. Moreover, plasma obtained from these patients recapitulated the modulation of NKG2D on healthy donors' NK cells, improving their trastuzumab-mediated activity in vitro. This enhancement occurred mainly using plasma from patients with low NKG2D basal expression. Our results indicate that taxanes increase tumor susceptibility to ADCC by acting on tumor and NK cells, and suggest that taxanes concomitantly administered with trastuzumab could maximize the antibody effect, especially in patients with low basal immune effector cytotoxic activity.

Original languageEnglish
Pages (from-to)255-265
Number of pages11
JournalOncotarget
Volume7
Issue number1
Publication statusPublished - 2016

Fingerprint

Antibody-Dependent Cell Cytotoxicity
Taxoids
Natural Killer Cells
NK Cell Lectin-Like Receptor Subfamily K
docetaxel
Breast Neoplasms
Neoplasms
Blocking Antibodies
Therapeutic Uses
Therapeutics
Trastuzumab
Theoretical Models
Tissue Donors
Ligands
Cell Line
Antibodies
Pharmaceutical Preparations
Population
In Vitro Techniques

Keywords

  • ADCC
  • Breast cancer
  • Docetaxel
  • NK cell
  • NKG2D

ASJC Scopus subject areas

  • Oncology

Cite this

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. / Di Modica, Martina; Sfondrini, Lucia; Regondi, Viola; Varchetta, Stefania; Oliviero, Barbara; Mariani, Gabriella; Bianchi, Giulia Valeria; Generali, Daniele; Balsari, Andrea; Triulzi, Tiziana; Tagliabue, Elda.

In: Oncotarget, Vol. 7, No. 1, 2016, p. 255-265.

Research output: Contribution to journalArticle

Di Modica, Martina ; Sfondrini, Lucia ; Regondi, Viola ; Varchetta, Stefania ; Oliviero, Barbara ; Mariani, Gabriella ; Bianchi, Giulia Valeria ; Generali, Daniele ; Balsari, Andrea ; Triulzi, Tiziana ; Tagliabue, Elda. / Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. In: Oncotarget. 2016 ; Vol. 7, No. 1. pp. 255-265.
@article{36312f80dad342ac8216972bd6b397b5,
title = "Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition",
abstract = "Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In HER2+ BC experimental models and patients, we investigated whether this synergy depends on the ability of drug-induced stress to improve NK cell effectiveness and thus trastuzumab-mediated ADCC. HER2+ BC cell lines BT474 and MDAMB361 treated with docetaxel showed up-modulation of NK activator ligands both in vitro and in vivo, accompanied by a 15-40{\%} increase in in vitro trastuzumab-mediated ADCC; antibodies blocking the NKG2D receptor significantly reduced this enhancement. NKG2D receptor expression was increased by docetaxel treatment in circulating and splenic NK cells from mice xenografted with tumor cells, an increase related to expansion of the CD11b+Ly6G+ cell population. Accordingly, NK cells derived from HER2+ BC patients after treatment with taxane-containing therapy expressed higher levels of NKG2D receptor than before treatment. Moreover, plasma obtained from these patients recapitulated the modulation of NKG2D on healthy donors' NK cells, improving their trastuzumab-mediated activity in vitro. This enhancement occurred mainly using plasma from patients with low NKG2D basal expression. Our results indicate that taxanes increase tumor susceptibility to ADCC by acting on tumor and NK cells, and suggest that taxanes concomitantly administered with trastuzumab could maximize the antibody effect, especially in patients with low basal immune effector cytotoxic activity.",
keywords = "ADCC, Breast cancer, Docetaxel, NK cell, NKG2D",
author = "{Di Modica}, Martina and Lucia Sfondrini and Viola Regondi and Stefania Varchetta and Barbara Oliviero and Gabriella Mariani and Bianchi, {Giulia Valeria} and Daniele Generali and Andrea Balsari and Tiziana Triulzi and Elda Tagliabue",
year = "2016",
language = "English",
volume = "7",
pages = "255--265",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "1",

}

TY - JOUR

T1 - Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition

AU - Di Modica, Martina

AU - Sfondrini, Lucia

AU - Regondi, Viola

AU - Varchetta, Stefania

AU - Oliviero, Barbara

AU - Mariani, Gabriella

AU - Bianchi, Giulia Valeria

AU - Generali, Daniele

AU - Balsari, Andrea

AU - Triulzi, Tiziana

AU - Tagliabue, Elda

PY - 2016

Y1 - 2016

N2 - Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In HER2+ BC experimental models and patients, we investigated whether this synergy depends on the ability of drug-induced stress to improve NK cell effectiveness and thus trastuzumab-mediated ADCC. HER2+ BC cell lines BT474 and MDAMB361 treated with docetaxel showed up-modulation of NK activator ligands both in vitro and in vivo, accompanied by a 15-40% increase in in vitro trastuzumab-mediated ADCC; antibodies blocking the NKG2D receptor significantly reduced this enhancement. NKG2D receptor expression was increased by docetaxel treatment in circulating and splenic NK cells from mice xenografted with tumor cells, an increase related to expansion of the CD11b+Ly6G+ cell population. Accordingly, NK cells derived from HER2+ BC patients after treatment with taxane-containing therapy expressed higher levels of NKG2D receptor than before treatment. Moreover, plasma obtained from these patients recapitulated the modulation of NKG2D on healthy donors' NK cells, improving their trastuzumab-mediated activity in vitro. This enhancement occurred mainly using plasma from patients with low NKG2D basal expression. Our results indicate that taxanes increase tumor susceptibility to ADCC by acting on tumor and NK cells, and suggest that taxanes concomitantly administered with trastuzumab could maximize the antibody effect, especially in patients with low basal immune effector cytotoxic activity.

AB - Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In HER2+ BC experimental models and patients, we investigated whether this synergy depends on the ability of drug-induced stress to improve NK cell effectiveness and thus trastuzumab-mediated ADCC. HER2+ BC cell lines BT474 and MDAMB361 treated with docetaxel showed up-modulation of NK activator ligands both in vitro and in vivo, accompanied by a 15-40% increase in in vitro trastuzumab-mediated ADCC; antibodies blocking the NKG2D receptor significantly reduced this enhancement. NKG2D receptor expression was increased by docetaxel treatment in circulating and splenic NK cells from mice xenografted with tumor cells, an increase related to expansion of the CD11b+Ly6G+ cell population. Accordingly, NK cells derived from HER2+ BC patients after treatment with taxane-containing therapy expressed higher levels of NKG2D receptor than before treatment. Moreover, plasma obtained from these patients recapitulated the modulation of NKG2D on healthy donors' NK cells, improving their trastuzumab-mediated activity in vitro. This enhancement occurred mainly using plasma from patients with low NKG2D basal expression. Our results indicate that taxanes increase tumor susceptibility to ADCC by acting on tumor and NK cells, and suggest that taxanes concomitantly administered with trastuzumab could maximize the antibody effect, especially in patients with low basal immune effector cytotoxic activity.

KW - ADCC

KW - Breast cancer

KW - Docetaxel

KW - NK cell

KW - NKG2D

UR - http://www.scopus.com/inward/record.url?scp=84995511494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995511494&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84995511494

VL - 7

SP - 255

EP - 265

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -